Under this new framework, regulators may be able to approve the treatment even when large patient populations don’t exist, if researchers can clearly show:
- How a disease works at the genetic, cellular, or molecular level;
- How a treatment addresses that mechanism, and
- Improvements that would not have been seen in patients without treatment.
This shift towards evaluating potential therapies based on how well they address specific mechanisms could speed up the development of rare disease treatments. It also means that it’s more important than ever to make sure patients and healthcare providers have a clear understanding of the science behind the disease and treatment so that they can make confident, informed decisions about their care.
Our other ideas worth exploring
A behavioural science perspective on pediatric caregiver education
By shifting from discrete tactics to holistic support, we can create better caregiver education in pediatric rare disease.
Patient transitions out of pre-launch programs
A look at the rare disease experience when clinical trials and expanded access programs end.
Cobra Effects for GenAI in Healthcare
Generative AI could totally transform healthcare. Goodhart’s Law helps us identify four watch-outs as models get more integrated into the delivery of care.



